Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance by unknown
ORIGINAL PAPER
Characteristics and clinical outcome of patients
with hypereosinophilia of undetermined significance
Grzegorz Helbig • Marek Hus • Tomasz Francuz •
Joanna Dziaczkowska-Suszek • Anna Soja •
Sławomira Kyrcz-Krzemien´
Received: 28 November 2013 / Accepted: 6 December 2013 / Published online: 14 December 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract The term ‘‘hypereosinophilia of undetermined
significance’’ (HEus) previously known as idiopathic,
benign eosinophilia relates to patients who have a long-
lasting, unexplained and asymptomatic blood HE. These
patients have not been studied so far in terms of demo-
graphic characteristics and clinical outcome. The aim of
this study was to present the clinical characteristics and
outcome of HEus patients. This is a retrospective, single-
center study of 40 patients with HEus. All patients under-
went the basic and specialized evaluations in order to rule
out the most common causes of blood HE, but no abnor-
malities were detected. Twelve patients with at least
moderate blood hypereosinophilia (defined as greater than
3.0 9 109/L) for more than 1-year duration were treated
with corticosteroids (CS) to avoid end-organ damage.
Twenty-one patients (52 %) had an increased leukocyte
count at diagnosis. Median blood eosinophilia was
4.2 9 109/L (range 1.5–55.4). HE [ 3.0 9 109/L was
demonstrated in 17 patients. 65 % of studied population
had an increased serum IgE levels, whereas only 2 %
demonstrated an increased serum vitamin B12 levels. A
median bone marrow infiltration by eosinophils was
30.5 % (range 11–78.2). All treated patients responded
promptly to CS and remained in complete remission while
receiving low doses of CS (20 mg/day to 5 mg every
2-day). One patient developed hypereosinophilic syndrome
(HES) after 11 years of follow-up. Further studies are
needed to define risk factors of HES development. The use
of CS for HEus patients is controversial and should be
individualized.
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Introduction
Blood hypereosinophilia (HE) remains a frequent finding
encountered in a daily clinical practice of different fields of
medicine. Under various conditions, eosinophils may pro-
duce and release a variety of biologically active substances
which may invade target organ and lead to its dysfunction
and/or damage. The harmful role of eosinophils results
from their inflammatory, fibrotic and thrombotic properties
[1]. The production and development of eosinophils are
regulated by several cytokines, but the role of interleukin
(IL)-5 was found to be essential. It is secreted by activated
T cells and to a lesser extent by mast cells and eosinophils
themselves [2].
The underlying causes of HE are diverse and can be
broadly divided into primary (clonal), secondary (reactive),
hereditary (familial) and idiopathic. The term HE should be
used when blood eosinophilia is greater than 1.5 9 109/L
on two occasions with a minimum of 1-month time inter-
val, and/or tissue HE is documented. The contemporary
definition of hypereosinophilic syndrome (HES) requires
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the presence of blood HE and an end-organ damage that
was proved to be eosinophilia related [3].
As the characteristics of different HES variants are well-
known [4], the outcome of patients with asymptomatic,
unexplained and persistent HE remains unclear. Herein, we
present the clinical and laboratory characteristics of 40
consecutive patients with idiopathic blood HE.
Materials and methods
All patients included in the study met the criteria for blood
HE, and they were recruited from several hematologic
centers in Poland between 1994 and 2013. The reasons why
the patients visited the primary care physician and per-
formed full blood test were following: random blood
investigation (n = 30), abdominal pain (n = 2), loss of
weight (n = 2), facial swelling (n = 1), joint pain (n = 1),
bone pain (n = 1), night sweats (n = 1), diarrhea (n = 1)
and dyspnoea (n = 1). All patients underwent the basic
evaluations at the primary care level including all neces-
sary tests in order to rule out the most common causes of
blood HE, but no abnormalities were detected. Physical
examination was normal as well as chest X-ray and
abdominal ultrasound. Originally reported complaints
resolved spontaneously after 2–3 days without treatment,
and they were found not to be HE related. Therefore, more
detailed imaging and endoscopic studies were not recom-
mended by a treating physician. Moreover, these symptoms
did not re-appear in the long-term observation.
Due to the persistent blood HE, these patients were
referred to a hematologist. All patients were free of any
symptoms. On admission a complete blood test with dif-
ferential, biochemistry and urinalysis were repeated. After
the blood HE has been confirmed, the more specialized
studies were initiated. Serum vitamin B12 and immuno-
globulin E (IgE) levels were measured. The presence of
infections caused by human immunodeficiency virus,
cytomegalovirus, Epstein-Barr virus, hepatitis B virus,
hepatitis C virus and toxocara was excluded using sero-
logical tests. Anti-nuclear antibodies as well as myeloper-
oxidase and proteinase 3 anti-neutrophil cytoplasmic
antibodies were ruled out. Every patient had negative
echocardiography and pulmonary function tests. No
patients had indications for computed tomography or
magnetic resonance imaging studies. Peripheral blood
T-lymphocytes were determined by flow cytometry tech-
nique on EPICS-XL-MCL (Beckman-Coulter, USA) using
monoclonal antibodies directed against T-cell surface
antigens: CD2, CD3, CD4, CD5, CD7, CD8, T-cell
receptor (TCR) ab and TCRcd, and no aberrant population
(including the most common CD3-CD4?) has been
detected. Polymerase chain reaction (PCR) was negative
for JAK2V617F, BCR-ABL and FIP1L1-PDGFRA molec-
ular abnormalities. Bone marrow cytology was normal
except eosinophilia. Bone marrow histology was not done.
Blood tests with differential, biochemistry, electrocardio-
gram, echocardiography, chest X-ray and abdominal
ultrasound were repeated every 3 months. Stool examina-
tion for ova and larvae was systematically repeated
throughout the study period, and it remained negative. The
study was approved by Local Ethics Committee by Silesian
Medical University, Katowice, Poland. Two patients from
the current study have been reported elsewhere [5].
Treatment and response
Twelve patients with at least moderate blood eosinophilia
(defined as greater than 3.0 9 109/L) for more than 1-year
duration were treated with corticosteroids to avoid end-
organ damage. The starting CS dose varied between
patients, and it was left to physician’s discretion. A com-
plete response (CR) was defined as a return of absolute
eosinophil count (AEC) to normal ranges (\0.7 9 109/L).
A maintenance dose was defined as the minimal effective
CS dose needed for CR maintenance. The response to CS
was assessed daily during the first week, then weekly
within the first month, and monthly thereafter.
Results
Forty patients (28 females and 12 males) at a median age at
diagnosis of 61 years (range 17–85) were included in this
retrospective study. A distant history of allergic skin
reactions and helminth infections was present for five and
four patients, respectively. Before entering the study, all
patients received tinidazole to prevent giardiasis with no
effect on blood eosinophilia. Twenty-one patients (52 %)
had an increased white blood cell (WBC) count at diag-
nosis. Hemoglobin concentration \12 g/dL and platelet
count \150 9 109/L were reported for nine and two
patients, respectively. These abnormalities normalized
spontaneously and were found not to be eosinophilia
related. Median AEC was 4.2 9 109/L (range 1.5–55.4).
An AEC greater than 3.0 9 109/L was demonstrated for 17
(40 %) patients. 65 % of studied patients had an increased
serum IgE levels, whereas only 2 % demonstrated an
increased serum vitamin B12 levels. A median bone mar-
row infiltration by eosinophils was 30.5 % (range 11–78.2).
No patient had an aberrant T-cell population on flow
cytometry, however, T helper (Th)/T suppressor (Ts) ratio
was found to be abnormal in eight patients. This ratio was
increased in three patients and decreased in five. Cytoge-
netic studies revealed normal diploid karyotype in 30
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patients, whereas no metaphases were obtained for the
remaining 10. The median follow-up of the studied popu-
lation was 55.2 months (range 6.4–231.4). Patients’ char-
acteristics are shown in Table 1.
Twelve out of the 17 patients with at least moderate blood
eosinophilia started the treatment with steroids whereas the
remaining five refused the therapy. The starting CS dose
varied between 5 and 60 mg daily, and the highest doses were
reserved for patients with severe blood HE. The maintenance
dose was fixed to maintain CR. All patients responded
promptly to CS and remained in CR while receiving low
doses of CS (20 mg/day to 5 mg every 2-day). The attempts
of treatment discontinuation while in CR failed, and the
patients were left on a minimal effective CS dose. No patient,
who originally refused the therapy, received the follow-up
treatment. Side effects of CS therapy were mild and included
bone and joint pain and malaise. None of the patients needed
CS dose reduction or discontinuation due to adverse events.
Twenty-seven patients who remained off therapy had a stable
blood HE, and no organ dysfunction was demonstrated during
follow-up. One female with no prior CS developed eosino-
philia-related cardiac failure after 11 years of sustained blood
HE, and she was successfully treated with CS. Details of CS
therapy are presented in Table 2.
Discussion
The term ‘‘hypereosinophilia of undetermined signifi-
cance’’ (HEus) previously known as idiopathic, benign
eosinophilia, relates to patients who have a long-lasting,
unexplained and asymptomatic blood HE. The pathogen-
esis and prognosis of such cases remain unknown, and its
clinical implication is to be validated. By definition, HEus
patients have no reactive and malignant causes of blood
HE. A family history remains also non-informative.
Moreover, these cases do not develop an eosinophilia-
related organ dysfunction or damage [3]. If so, they should
be classified as HES. There are lacking prospective studies
involving this patient population, especially in regard to
clinical and laboratory characteristics as well as long-term
follow-up. The risk of HES development in a long-dated
observation remains unknown. There is also no consensus
regarding CS introduction for these patients. Bearing all
these issues in mind, this retrospective analysis was done.
Only single retrospective studies on a natural history of
blood HE have been published so far [6, 7]. In fact, most
reported patients had well-defined causes of HE, and only a
small minority of cases was actually idiopathic. Thus,
regarding these two large reports, we focus on the patients
with idiopathic blood HE. Unfortunately, both reports had
many drawbacks resulting from their retrospective nature.
A recently published report [6] recruited 33 patients with
presumably HEus, but in fact, the appropriate diagnostic
work-up was performed in a minority of them, and it was
restricted to some common investigations. Nevertheless,
the presumably HEus patients had AEC greater than
5.0 9 109/L and an increased serum IgE levels. Most
patients were treated with steroids and achieved a long-
term response, but the doses of CS were not provided.
Surprisingly, the median time to response to CS exceeded
2 months.
The other retrospective study included 100 hospitalized
patients with blood HE, and 34 % of them had an unknown
etiology despite an extensive panel of investigations [7].
















1. 3.73 11.9 15 5 every 2-day \7
2. 4.25 1,143.0 20 10 \7
3. 3.55 1,033.0 10 10/5 alternately 14
4. 31.1 19.4 60 20 14
5. 3.1 528.0 20 5 \7
6. 3.8 2,550.0 10 5 \7
7. 4.65 43.0 5 5 14
8. 8.5 1,080.0 30 10 \7
9. 7.9 4,089.0 30 10 \7
10. 21.4 3,648.0 30 10 \7
11. 15.8 176.0 40 10 14
12. 55.4 361.0 60 20 14
AEC absolute eosinophil count, CS corticosteroids, CR complete response
Table 1 Study group characteristics
Parameter HEUS (n)
Number of patients 40
Gender: male/female 12/28
Median age (range; years) 61 (17–85)
WBCa count (9109/L) 11.2 (5.5–70.1)
WBC [ 10 (9109/L) 52 %
Hemoglobin (g/dL) 13.0 (8.7–19.1)
Hemoglobin \12 (g/dL) 22 %
Platelet count (9109/L) 289 (68–605)
Platelet count \150 (9109/L) 2 %
AECb (9109/L) 4.2 (1.5–55.4)
AEC [3 9 109/L 42 %
Eosinophils in bone marrow (%) 30.5 (11–78.2)
Serum IgE (IU/mL)c 528 (11.9–4,089)
Serum IgE [ Nc 67 %
Serum B12 vitamin (pg/mL)c 333 (149–1,431)
Serum B12 [ Nc 2 %
a WBC white blood cell, b AEC absolute eosinophil count, c normal
ranges (N): IgE\100 IU/mL; for vitamin B12 level: 157–1,057 pg/mL
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This figure has also been demonstrated by others [8, 9].
Conversely, only 3 % of the patients had unexplained HE
in a large study reported by Lombardi et al. [10]. However,
one should keep in mind that all these studies were based
on a chart review and they had many limitations resulting
from its retrospective nature. Moreover, they did not pro-
vide the results of molecular studies (e.g., FIP1L1-PDG-
FRA). There was also lacking data on the clinical outcome
in a long-term follow-up. Nevertheless, the vast majority of
detected blood eosinophilias was associated with allergic
processes [7, 8]. Kobayashi et al. [11] defined the threshold
of blood HE that may indicate the presence of HES and
distinguished it from bronchial asthma. It was demon-
strated that AEC greater than 2.052 9 109/L was strongly
suggestive of HES, and this value was associated with a
higher risk of organ damage. These patients had also high
serum IgE levels. However, one should keep in mind that
the definition of HES provided by authors differed signif-
icantly from that used nowadays. In a very recent paper,
Chen et al. [12] reported on eight patients who met the
current HEus criteria [3]. When they compared the labo-
ratory data between HEus and untreated HES subjects, they
found no difference except for a higher serum IgE and IL-
13 levels in the latter group. Surprisingly, 50 % of HEus
patients had an aberrant T-cell population, but none of
them developed clinical symptoms or organ damage [12].
The risk factors of HES development have not been
established so far. Only one patient from our study cohort
developed HES, and it has been 11 years since blood HE was
detected. That was female with AEC varied between
1.5 9 109–2.5 9 109/L during the whole follow-up, with a
slightly increased serum IgE level (146 IU/mL; normal range
\100 IU/mL) and an abnormal Th/Ts ratio (0.7) at HEus
diagnosis. At the time of HES development, this case was
deeper evaluated. Namely, a study for T-cell receptor clonal
rearrangement by PCR was performed, and it was found to be
positive. Serum thymus and activation-regulated chemokine
and interleukin (IL)-5 levels using commercially available
ELISA kits were also measured, and they were following:
178.7 pg/mL (sensitivity [7 pg/mL) and 6.6 (sensitivity
[1.08 pg/mL), respectively. Taken together, the diagnosis
of lymphocytic-HES was established.
Despite the fact that blood AEC was greater than
3.0 9 109/L in more than 40 % of study patients and serum
IgE levels exceeded normal ranges in almost 70 % of them,
the organ involvements were not detected in subsequent
imaging studies. However, the median duration of follow-
up for our patient population is less than 5 years. Older
reports demonstrated that HES may develop after
8–9 years of sustained blood HE [13]. Currently, it is dif-
ficult to support the thesis that a benign idiopathic blood
HE is a smoldering form of HES. To confirm this
hypothesis, the markers of eosinophil activity were
measured in a patient with a long-standing blood HE. The
test showed an impaired function of eosinophils, but it did
not explain why and when they become deleterious to the
organs [14].
Another interesting aspect relates to the early drug
therapy for asymptomatic patients with HEus. There is no
evidence that the introduction of CS, despite the lack of
symptoms, will influence the natural history of these
patients and prevent the HES development. It should be
highlighted that the treatment with CS for HEus remains
controversial, and currently, there is no data supporting this
approach. In a daily clinical practice, the decision who and
when should receive the treatment is left to the treating
physician, e.g., Mayo Group preference is to start the
treatment when AEC is considered too high, but this
threshold is not established [15]. Some authors recommend
an AEC greater than 2.0 9 109/L as an indication for
treatment [16]. One should keep in mind that a sustained
high blood HE remains frustrating both for clinician and for
a patient, but it should not justify a durable CS treatment.
Twelve patients with HEus received steroids in our cohort. It
was due to a high number of circulating blood eosinophils
and the risk of organ damage. All treated patients responded
to CS, and the dose was promptly reduced to maintain
remission. Five patients were left on higher CS maintenance
doses (10–20 mg daily), and it was due to their very high
blood HE at diagnosis (from 7.9 9 109 to 55.0 9 109/L). In
fact, the exposure to the higher CS dose was short, and
therefore, the observed side effects were irrelevant. Nev-
ertheless, all patients receive proton pump inhibitor as
prophylaxis against gastric ulcers. They are also systemat-
ically monitored for potential complications. The median
duration of CS treatment is 8 weeks (range 2–24 weeks).
The attempts of CS discontinuation failed. A female patient
who developed HES was free of CS until the cardiac failure
occurred. She responded to the treatment and remains in
remission with normal cardiac function while still on CS.
Conclusions
The pathogenesis and the clinical relevance of HEus remain
to be elucidated. Every patient with HEus requires the
comprehensive evaluation to exclude various reactive and
neoplastic eosinophilia-related conditions according to a
contemporary consensus of multidisciplinary experts in the
field of eosinophilia [3]. An international prospective study
with a larger patient population and a longer follow-up is
strongly required to define the risk factors of HES devel-
opment. The use of CS for HEus patients should be indi-
vidualized paying special attention to adverse drug
reactions. It seems reasonable to plan a randomized study
in order to assess the benefit of CS in HEus.
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